Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $13.11 $15.83 Friday, 10th May 2024 SRRK stock ended at $13.35. This is 8.25% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 8.97% from a day low at $13.19 to a day high of $14.37.
90 days $12.81 $17.90
52 weeks $5.56 $21.17

Historical Scholar Rock Holding Corp. prices

Date Open High Low Close Volume
Apr 05, 2024 $14.25 $14.64 $13.93 $14.39 480 772
Apr 04, 2024 $15.32 $15.80 $14.36 $14.40 551 028
Apr 03, 2024 $15.65 $15.95 $14.93 $15.23 650 343
Apr 02, 2024 $16.26 $16.73 $15.55 $15.72 724 207
Apr 01, 2024 $17.60 $17.65 $16.35 $16.79 881 554
Mar 28, 2024 $17.19 $17.90 $15.27 $17.76 1 749 804
Mar 27, 2024 $15.16 $15.54 $15.13 $15.45 582 382
Mar 26, 2024 $16.23 $16.43 $14.92 $15.00 1 027 358
Mar 25, 2024 $16.18 $16.94 $15.73 $16.01 632 043
Mar 22, 2024 $17.11 $17.35 $16.31 $16.39 801 512
Mar 21, 2024 $16.80 $17.22 $15.66 $17.20 2 273 447
Mar 20, 2024 $14.98 $16.88 $14.97 $16.45 1 964 505
Mar 19, 2024 $12.81 $15.26 $12.81 $15.15 1 605 959
Mar 18, 2024 $14.23 $14.42 $13.12 $13.20 867 458
Mar 15, 2024 $14.72 $15.13 $14.30 $14.45 4 139 731
Mar 14, 2024 $16.14 $16.50 $14.72 $14.78 642 216
Mar 13, 2024 $16.42 $16.98 $16.14 $16.38 585 810
Mar 12, 2024 $16.22 $16.77 $15.88 $16.61 734 457
Mar 11, 2024 $17.19 $17.42 $16.24 $16.28 825 134
Mar 08, 2024 $16.89 $17.24 $16.21 $16.98 850 550
Mar 07, 2024 $16.59 $16.66 $15.40 $16.02 911 290
Mar 06, 2024 $16.01 $16.65 $16.01 $16.38 804 965
Mar 05, 2024 $15.72 $17.04 $15.38 $15.82 2 030 813
Mar 04, 2024 $15.99 $15.99 $14.73 $15.36 659 352
Mar 01, 2024 $15.49 $16.00 $15.33 $15.68 647 037
Click to get the best stock tips daily for free!

About Scholar Rock Holding Corp.

Scholar Rock Holding . Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria... SRRK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT